Anterior uveitis in a patient receiving evolocumab

Vega‐Morales, David; Vázquez-Fuentes, Brenda Roxana; Esquivel-Valerio, Jorge Antonio; Galarza‐Delgado, Dionicio Ángel

doi:10.24875/rmu.20000009

Cited by 2 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, if some cholesterol had to be presented as an autoantigen through the cornea or AC, no or minimal immune response could be expected due to the AC-associated immune deviation phenomenon. This could, however, all be compromised if corneal neovascularisation or previous intraocular inflammation has occurred, which is what the authors suggest 18 19…”

Section: Discussionmentioning

confidence: 88%

Alirocumab-associated unilateral posterior uveitis

Inegbedion,

Azzopardi,

Inessa

et al. 2024

BMJ Case Rep

View full text Add to dashboard Cite

A man in his mid-40s who had been recently started on alirocumab (a human monoclonal antibody which inhibits proprotein convertase subtilisin/kexin type 9) due to his strong familial cardiovascular risk and refractory hypercholesterolaemia presented with a few-hour history of acute-onset left-sided blurred vision. The best-corrected visual acuities were 6/6 bilaterally and slit-lamp examination was normal. However, optical coherence tomography revealed serous subretinal fluid in the left macula. Optos ultra-widefield retinal imaging and fundus autofluorescence, along with a set of blood tests, did not reveal any alternative causes. A diagnosis of alirocumab-associated uveitis was diagnosed. Alirocumab was stopped and he was followed up in uveitis clinic. Within 4 months following alirocumab cessation, the subretinal fluid resolved completely. This case report emphasises the importance of early multidisciplinary team involvement, since novel therapeutic agents can have unexpected adverse events.

show abstract

Section: Discussionmentioning

confidence: 88%

Alirocumab-associated unilateral posterior uveitis

Inegbedion,

Azzopardi,

Inessa

et al. 2024

BMJ Case Rep

View full text Add to dashboard Cite

show abstract

“…Comorbidities, as components of these heterogeneous features, often coexist with KOA and are particularly prevalent in end-stage KOA. The impact of comorbidities on end-stage KOA is extensive and includes increased health care use and costs, impaired physical and mental health, increased mortality, and reduced quality of life [6][7][8] . Therefore, it is important to identify the complex relationship between end-stage KOA and comorbidities.…”

Section: Introductionmentioning

confidence: 99%

Clinical phenotypes of comorbidities in end-stage knee osteoarthritis: a cluster analysis

liu,

Ma,

Zhang

et al. 2023

Preprint

View full text Add to dashboard Cite

Objectives Comorbidities, as components of these heterogeneous features, often coexist with knee osteoarthritis, and are particularly prevalent in end-stage knee osteoarthritis. Here, we attempted to identify the different clinical phenotypes of comorbidities in patients with end-stage knee osteoarthritis by cluster analysis. Methods A total of 421 inpatients diagnosed with end-stage knee osteoarthritis who underwent inpatient surgery were included in this cross-sectional study. 23 demographic, comorbidity, inflammatory immune and evaluation scale variables were collected. Systematic clustering after factor analysis and separate two-step cluster analysis were performed for individual comorbidity variables and all variables, respectively, to objectively identify the different clinical phenotypes of the study patients. Results Four clusters were finally identified. Cluster 1 had the largest proportion of obese patients (93.8%) and hypertension was common (71.2%). Almost all patients in cluster 2 were depressed (95.8%) and anxiety disorders (94.7%). Cluster 3 combined patients with isolated end-stage knee osteoarthritis and a few comorbidities. Cluster 4 had the highest proportion of patients with rheumatoid arthritis (58.8%). Conclusions Patients with end-stage knee osteoarthritis may be classified into four different clinical phenotypes: "isolated end-stage knee osteoarthritis"; "obesity + hypertension"; "depression + anxiety"; and "rheumatoid arthritis", which may help guide individualized patient care and treatment strategies.

show abstract

Anterior uveitis in a patient receiving evolocumab

Cited by 2 publications

References 22 publications

Alirocumab-associated unilateral posterior uveitis

Alirocumab-associated unilateral posterior uveitis

Clinical phenotypes of comorbidities in end-stage knee osteoarthritis: a cluster analysis

Contact Info

Product

Resources

About